159 related articles for article (PubMed ID: 10449288)
41. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
Piketty C; Castiel P; Belec L; Batisse D; Si Mohamed A; Gilquin J; Gonzalez-Canali G; Jayle D; Karmochkine M; Weiss L; Aboulker JP; Kazatchkine MD
AIDS; 1998 May; 12(7):745-50. PubMed ID: 9619806
[TBL] [Abstract][Full Text] [Related]
42. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
d'Arminio Monforte A; Lepri AC; Rezza G; Pezzotti P; Antinori A; Phillips AN; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
AIDS; 2000 Mar; 14(5):499-507. PubMed ID: 10780712
[TBL] [Abstract][Full Text] [Related]
43. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
44. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection.
Lillo FB; Ciuffreda D; Veglia F; Capiluppi B; Mastrorilli E; Vergani B; Tambussi G; Lazzarin A
AIDS; 1999 May; 13(7):791-6. PubMed ID: 10357377
[TBL] [Abstract][Full Text] [Related]
45. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
[TBL] [Abstract][Full Text] [Related]
46. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection.
Giorgi JV; Majchrowicz MA; Johnson TD; Hultin P; Matud J; Detels R
AIDS; 1998 Oct; 12(14):1833-44. PubMed ID: 9792384
[TBL] [Abstract][Full Text] [Related]
47. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
48. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
Miller V; Sabin CA; Phillips AN; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm EB; Staszewski S
AIDS; 2000 Sep; 14(14):2129-36. PubMed ID: 11061654
[TBL] [Abstract][Full Text] [Related]
49. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
[TBL] [Abstract][Full Text] [Related]
50. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
51. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire.
Djomand G; Roels T; Ellerbrock T; Hanson D; Diomande F; Monga B; Maurice C; Nkengasong J; Konan-Koko R; Kadio A; Wiktor S; Lackritz E; Saba J; Chorba T
AIDS; 2003 Jul; 17 Suppl 3():S5-15. PubMed ID: 14565604
[TBL] [Abstract][Full Text] [Related]
52. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
Sterling TR; Chaisson RE; Moore RD
AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
[TBL] [Abstract][Full Text] [Related]
53. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
[TBL] [Abstract][Full Text] [Related]
54. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
55. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
[TBL] [Abstract][Full Text] [Related]
56. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
57. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
58. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
59. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Lucas GM; Chaisson RE; Moore RD
AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
[TBL] [Abstract][Full Text] [Related]
60. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]